Tokyo Tape
Sign in
← ReproCELL

Half-year report · Q2

4978.TEDINET S100UOVO
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 43
MetricValuePeriodScopeSource row
Revenue¥1.3bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥2.4bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥1.1bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income−¥149m2024-04-01 → 2024-09-30Cons.Operating income
Operating income−¥242m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥103m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥40m2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥70m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥103m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥62m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥104m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥31m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥61m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥104m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥61m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥9.4bnat 2024-09-30Cons.Assets
Total assets¥9.1bnat 2024-03-31Cons.Assets
Total assets¥8.4bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥679mat 2024-09-30Cons.Liabilities
Total liabilities¥741mat 2024-03-31Cons.Liabilities
Net assets / equity¥8.7bnat 2024-09-30Cons.Net assets
Net assets / equity¥8.3bnat 2024-03-31Cons.Net assets
Net assets / equity¥7.7bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.0bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥2.9bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥3.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.9bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow−¥131m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥11m2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥58m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥412m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥404m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥46m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥681m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥544m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-1.142024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-0.372023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥0.712023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio92.8%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio91.8%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio92.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment ordinary income2024-04-01 → 2024-09-30−¥378m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥176m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥176m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentsegment ordinary income2024-04-01 → 2024-09-30¥8m
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥1.1bn
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥1.1bn
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentsegment ordinary income2024-04-01 → 2024-09-30¥267m
—segment totalrevenue2024-04-01 → 2024-09-30¥1.3bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥1.3bn
—segment totalsegment ordinary income2024-04-01 → 2024-09-30¥275m
Reconciling Itemsreconcilingsegment ordinary income2023-04-01 → 2023-09-30−¥214m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥122m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥122m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentsegment ordinary income2023-04-01 → 2023-09-30¥110m
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.0bn
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.0bn
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentsegment ordinary income2023-04-01 → 2023-09-30¥174m
—segment totalrevenue2023-04-01 → 2023-09-30¥1.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥1.1bn
—segment totalsegment ordinary income2023-04-01 → 2023-09-30¥284m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 483
ItemContextValueUnit
Operating incomePrior1YTDDuration-241565000JPY
Operating incomeCurrentYTDDuration-149176000JPY
Interest income noiPrior1YTDDuration23921000JPY
Interest income noiCurrentYTDDuration31160000JPY
Subsidy income noiPrior1YTDDuration204772000JPY
Subsidy income noiCurrentYTDDuration14611000JPY
Foreign exchange gains noiPrior1YTDDuration70077000JPY
Foreign exchange gains noiCurrentYTDDuration－JPY
Other noiPrior1YTDDuration16806000JPY
Other noiCurrentYTDDuration11678000JPY
Non operating incomePrior1YTDDuration315578000JPY
Non operating incomeCurrentYTDDuration57450000JPY
Loss on investments in partnership noePrior1YTDDuration720000JPY
Loss on investments in partnership noeCurrentYTDDuration－JPY
Equity in losses of affiliates noePrior1YTDDuration2404000JPY
Equity in losses of affiliates noeCurrentYTDDuration3735000JPY
Amortization of restricted stock compensation noePrior1YTDDuration－JPY
Amortization of restricted stock compensation noeCurrentYTDDuration4104000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration2937000JPY
Other noePrior1YTDDuration610000JPY
Other noeCurrentYTDDuration754000JPY
Non operating expensesPrior1YTDDuration3736000JPY
Non operating expensesCurrentYTDDuration11531000JPY
Ordinary incomePrior1YTDDuration70276000JPY
Ordinary incomeCurrentYTDDuration-103257000JPY
Loss on valuation of investment securities elPrior1YTDDuration8349000JPY
Loss on valuation of investment securities elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration8349000JPY
Extraordinary lossCurrentYTDDuration－JPY
Income before income taxesPrior1YTDDuration61926000JPY
Income before income taxesCurrentYTDDuration-103257000JPY
Income taxes currentPrior1YTDDuration1124000JPY
Income taxes currentCurrentYTDDuration962000JPY
Income taxesPrior1YTDDuration1124000JPY
Income taxesCurrentYTDDuration962000JPY
Profit lossPrior1YTDDuration60802000JPY
Profit lossCurrentYTDDuration-104219000JPY
Profit loss attributable to owners of parentPrior1YTDDuration60802000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-104219000JPY
Profit lossPrior1YTDDuration60802000JPY
Profit lossCurrentYTDDuration-104219000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration59130000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-82687000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration42653000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration-27323000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration6633000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration-35016000JPY
Other comprehensive incomePrior1YTDDuration108417000JPY
Other comprehensive incomeCurrentYTDDuration-145027000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass